What is BRNS's net income for the last quarter?

BRNS's net income for the last quarter is -10.58B USD.

Can I buy BRNS shares in India?

Yes. You can buy BRNS in India by opening an international trading account.

Barinthus Biotherapeutics plc American Depositary Shares Share Price Live Today – NASDAQ:BRNS Stock Price, Chart, News, History

Q: What is Barinthus Biotherapeutics plc American Depositary Shares share price today?

Barinthus Biotherapeutics plc American Depositary Shares share price today is $0.00 as on October 30, 2026 at 5:51 am IST.

Q: What is the 52 week high and 52 week low of Barinthus Biotherapeutics plc American Depositary Shares stock?

52 week high/low data for Barinthus Biotherapeutics plc American Depositary Shares is currently unavailable.

Barinthus Biotherapeutics plc American Depositary Shares Stock Performance

Open N/A	Prev. Close N/A	Circuit Range N/A
Day Range N/A	Year Range N/A	Volume N/A
Average Traded N/A

Barinthus Biotherapeutics plc American Depositary Shares Share Price Chart

$0.00$0.00

L

H

Barinthus Biotherapeutics plc American Depositary Shares Stock Fundamentals & Key Indicators

Market Cap N/A	PE Ratio (TTM) N/A	Dividend Yield 0.00%
EPS (TTM) $-1.02	Revenue (TTM) $0.00	Return On Equity (TTM) -73.18%
Profit Margin N/A	Debt to Equity 0.00	Quarterly Earnings Growth YoY 27.39%

Barinthus Biotherapeutics plc American Depositary Shares Quarterly Profit & Loss

All figures in USD

Particulars	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	$0.00	$0.00	$0.00	$0.00
Net Profit	-$14.57	-$11.09	-$5.53	-$10.58
Net Profit Margin	N/A	N/A	N/A	N/A
Income Change	N/A	23.88%	50.14%	-91.32%

Barinthus Biotherapeutics plc American Depositary Shares Annual Profit & Loss

All figures in USD

Particulars	2023	2024	2025
Revenue	$0.80	$14.97	$0.00
Net Profit	-$73.35	-$61.07	-$66.43
Net Profit Margin	-9168.75%	-407.95%	N/A
Income Change	N/A	16.74%	-8.78%

About Barinthus Biotherapeutics plc American Depositary Shares

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Barinthus Biotherapeutics plc American Depositary Shares Historical Returns

Share price history by day, with open and close prices and the day's change
Month	Open	Close	Change %

Barinthus Biotherapeutics plc American Depositary Shares Share Price